Blau Farmacêutica S.A. (BVMF: BLAU3)
Brazil
· Delayed Price · Currency is BRL 14.05
+0.55 (4.07%)
Dec 20, 2024, 6:07 PM GMT-3
Blau Farmacêutica Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,686 | 1,373 | 1,407 | 1,366 | 1,182 | 977.5 | Upgrade
|
| Revenue Growth (YoY) | 24.70% | -2.44% | 2.96% | 15.62% | 20.90% | 24.97% | Upgrade
|
| Cost of Revenue | 1,089 | 882.38 | 739.03 | 700.47 | 625.84 | 547.44 | Upgrade
|
| Gross Profit | 596.47 | 490.25 | 667.88 | 665.93 | 555.97 | 430.07 | Upgrade
|
| Selling, General & Admin | 304.27 | 269.28 | 213.85 | 201.77 | 161.36 | 127.19 | Upgrade
|
| Other Operating Expenses | 10.15 | -117.75 | 1.83 | 5.41 | 4.93 | 1.59 | Upgrade
|
| Operating Expenses | 330.6 | 160.97 | 215.69 | 209.31 | 166.83 | 128.59 | Upgrade
|
| Operating Income | 265.88 | 329.28 | 452.19 | 456.62 | 389.13 | 301.48 | Upgrade
|
| Interest Expense | -64.35 | -32.11 | -32.43 | -26.8 | -15.32 | -15.12 | Upgrade
|
| Interest & Investment Income | 50.04 | 55.8 | 70.22 | 34.95 | 5.23 | 6.24 | Upgrade
|
| Earnings From Equity Investments | 0.04 | 0.16 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -5.4 | -8.6 | -4.45 | 1.23 | -24.77 | -6.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -7.96 | -10.3 | -16.97 | 16.46 | -0.63 | 0.24 | Upgrade
|
| Pretax Income | 238.24 | 334.23 | 468.56 | 482.47 | 353.64 | 286.36 | Upgrade
|
| Income Tax Expense | 54.8 | 86.74 | 108.07 | 158.6 | 99.31 | 86.13 | Upgrade
|
| Earnings From Continuing Operations | 183.44 | 247.49 | 360.49 | 323.86 | 254.33 | 200.24 | Upgrade
|
| Minority Interest in Earnings | 3.61 | 2.32 | 2.88 | 1.36 | - | - | Upgrade
|
| Net Income | 187.05 | 249.81 | 363.37 | 325.22 | 254.33 | 200.24 | Upgrade
|
| Net Income to Common | 187.05 | 249.81 | 363.37 | 325.22 | 254.33 | 200.24 | Upgrade
|
| Net Income Growth | -41.02% | -31.25% | 11.73% | 27.87% | 27.01% | 62.46% | Upgrade
|
| Shares Outstanding (Basic) | 178 | 178 | 178 | 179 | 148 | 148 | Upgrade
|
| Shares Outstanding (Diluted) | 178 | 178 | 178 | 179 | 158 | 151 | Upgrade
|
| Shares Change (YoY) | -0.08% | -0.08% | -0.87% | 13.84% | 4.39% | 2.00% | Upgrade
|
| EPS (Basic) | 1.05 | 1.41 | 2.04 | 1.81 | 1.72 | 1.35 | Upgrade
|
| EPS (Diluted) | 1.05 | 1.41 | 2.04 | 1.81 | 1.61 | 1.33 | Upgrade
|
| EPS Growth | -40.96% | -31.18% | 12.69% | 12.33% | 21.68% | 59.27% | Upgrade
|
| Free Cash Flow | 214.17 | 71.14 | 29.24 | 5.93 | 143.91 | 138.92 | Upgrade
|
| Free Cash Flow Per Share | 1.21 | 0.40 | 0.16 | 0.03 | 0.91 | 0.92 | Upgrade
|
| Dividend Per Share | - | - | 0.644 | - | - | - | Upgrade
|
| Gross Margin | 35.38% | 35.72% | 47.47% | 48.74% | 47.04% | 44.00% | Upgrade
|
| Operating Margin | 15.77% | 23.99% | 32.14% | 33.42% | 32.93% | 30.84% | Upgrade
|
| Profit Margin | 11.10% | 18.20% | 25.83% | 23.80% | 21.52% | 20.48% | Upgrade
|
| Free Cash Flow Margin | 12.70% | 5.18% | 2.08% | 0.43% | 12.18% | 14.21% | Upgrade
|
| EBITDA | 302.15 | 362.76 | 469.62 | 474.85 | 404.94 | 310.86 | Upgrade
|
| EBITDA Margin | 17.92% | 26.43% | 33.38% | 34.75% | 34.26% | 31.80% | Upgrade
|
| D&A For EBITDA | 36.27 | 33.47 | 17.43 | 18.22 | 15.81 | 9.39 | Upgrade
|
| EBIT | 265.88 | 329.28 | 452.19 | 456.62 | 389.13 | 301.48 | Upgrade
|
| EBIT Margin | 15.77% | 23.99% | 32.14% | 33.42% | 32.93% | 30.84% | Upgrade
|
| Effective Tax Rate | 23.00% | 25.95% | 23.06% | 32.87% | 28.08% | 30.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.